AME
75
6
EA
65
2
PM
56
-2
EIX
70
-2
GLW
53
-2
BXP
47
-7
CAT
62
-2
AEP
45
-2
SWK
62
-3
PPL
52
-2
ETN
83
-3
FLS
78
-2
ACN
65
16
GILD
60
-3
CME
61
2
IRM
41
-3
STI
12
-2
EW
29
-3
ADSK
72
-3
FAST
64
-3
AME
75
6
EA
65
2
PM
56
-2
EIX
70
-2
GLW
53
-2
BXP
47
-7
CAT
62
-2
AEP
45
-2
SWK
62
-3
PPL
52
-2
ETN
83
-3
FLS
78
-2
ACN
65
16
GILD
60
-3
CME
61
2
IRM
41
-3
STI
12
-2
EW
29
-3
ADSK
72
-3
FAST
64
-3
Financhill
Back

Pacira BioSciences Quote, Financials, Valuation and Earnings

Trump's "Document 20" Revealed: Smart Americans Could Get Rich During His 2nd Term

See if stocks could soar as much as 1,000% if history repeats itself.
Sell
35

PCRX
Pacira BioSciences

Last Price:
16.45
Seasonality Move:
14.03%

7 Day Trial

ALL ACCESS PASS

$ 7

Write This Down: Tuesday at 2 p.m. ET!

Don't Miss Our LIVE Trade

Pacira BioSciences Price Quote

$16.45
-0.36 (-2.14%)
(Updated: November 13, 2024 at 5:55 PM ET)

Pacira BioSciences Key Stats

Sell
35
Pacira BioSciences (PCRX) is a Sell
Day range:
$16.40 - $17.54
52-week range:
$11.16 - $35.95
Dividend yield:
0%
P/E ratio:
18.89
P/S ratio:
1.32
P/B ratio:
1.04%
Volume:
732.3K
Avg. volume:
577.5K
1-year change:
-40.98%
Market cap:
$776.2M
Revenue:
$675M
EPS:
$-2.01

How Much Does Pacira BioSciences Make?

Is Pacira BioSciences Growing As A Company?

  • What Is Pacira BioSciences's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.03%
  • What Is Pacira BioSciences's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Pacira BioSciences Stock Price Performance

What Is Pacira BioSciences 52-Week High & Low?

Pacira BioSciences Price To Free Cash Flow

Is It Risky To Buy Pacira BioSciences?

  • How Much Debt Does Pacira BioSciences Have?
    Total long term debt quarterly is $587.4M
  • How Much Cash Does Pacira BioSciences Have?
    Cash and short term investments quarterly total is $453.8M
  • What Is Pacira BioSciences’s Book Value Per Share?
    Book value per share is 16.24

Is Pacira BioSciences Cash Flow Positive?

  • What Is PCRX Cash Flow From Operations?
    Cash flow from operations (TTM) is $203.8M
  • What Is Pacira BioSciences’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $17.5M
  • What Is Pacira BioSciences’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$74.5M

Pacira BioSciences Return On Invested Capital

  • Is Management Doing A Good Job?
    PCRX return on invested capital is -6.51%
  • What Is Pacira BioSciences Return On Assets?
    ROA measures how assets are converting to revenues and is -5.77%
  • What Is PCRX Return On Equity?
    ROE is a measure of profitability and is -10.74%

Pacira BioSciences Earnings Date & Stock Price

Pacira BioSciences Competitors

  • Who Are Pacira BioSciences's Competitors?
    Below is a list of companies who compete with Pacira BioSciences or are related in some way:
    • Cyclo Therapeutics Inc (CYTH)
    • iBio Inc (IBIO)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Palatin Technologies Inc (PTN)
    • Revance Therapeutics Inc (RVNC)

Pacira BioSciences Dividend Yield

Pacira BioSciences Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 12.07%
Revenue: 2.84% -0.55%

Analyst Recommendations

Buy Recommendations: 1
Hold Recommendations: 4
Sell Recommendations: 1
Price Target: 18.00
Upside from Last Price: 7.08%

Major Shareholders

  • How many PCRX shares are owned by institutional investors?
    69.2M PCRX shares are owned by institutional investors
  • How many PCRX shares are owned by insiders?
    1.3M PCRX shares are owned by insiders